Successful use of Tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis

References

• Rajkumar SV, Gertz MA. Advances in the treatment of amyloidosis. N Engl J Med 2007;356:2413–2415.
   PubMedGoogle Scholar
• Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, Combe B, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003;48:2019–2024.
   PubMed Web of Science ®Google Scholar
• Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro MC, Olivé A, de Haro M, Portales RG, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 2005;118:552–556.
   PubMed Web of Science ®Google Scholar
• Global tuberculosis control. WHO Report 2010. Geneva, WHO 2010(document WHO/HTM/TB/2010.7)
   Google Scholar
• Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361–2371.
   PubMed Web of Science ®Google Scholar
• Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009;61:1435–1440.
   PubMed Web of Science ®Google Scholar
• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583–596.
   PubMed Web of Science ®Google Scholar
• Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006;8 Suppl 2:S3.
   Google Scholar
• Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898–909.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24–29.
   PubMed Web of Science ®Google Scholar
• Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol 2006;17:3458–3471.
   PubMed Web of Science ®Google Scholar
• Verschueren P, Lensen F, Lerut E, Claes K, De Vos R, Van Damme B, Westhovens R. Benefit of anti-TNFα treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis 2003;62:368–369.
   PubMedGoogle Scholar
• Seida A, Wada J, Morita Y, Baba M, Eguchi J, Nishimoto N, Okino T, et al. Multicentric Castleman’s disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury? Am J Kidney Dis 2004;43:E3–E9.
   Google Scholar
• Dubrey SW, Cha K, Simms RW, Skinner M, Falk RH. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol 1996;77:313–315.
   PubMed Web of Science ®Google Scholar
• Falk RH, Plehn JF, Deering T, Schick EC Jr, Boinay P, Rubinow A, Skinner M, Cohen AS. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol 1987;59:418–422.
   PubMed Web of Science ®Google Scholar
• Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50:2101–2110.
   PubMed Web of Science ®Google Scholar
• Sattianayagam P, Hawkins P, Gillmore J. Amyloid and the GI tract. Expert Rev Gastroenterol Hepatol 2009;3:615–630.
   PubMedGoogle Scholar
• Hayman SR, Lacy MQ, Kyle RA, Gertz MA. Primary systemic amyloidosis: a cause of malabsorption syndrome. Am J Med 2001;111:535–540.
   PubMed Web of Science ®Google Scholar
• Ozdemir D, Dagdelen S, Erbas T, Sokmensuer C, Erbas B, Cila A. Amyloid goiter and hypopituitarism in a patient with systemic amyloidosis. Amyloid 2011;18:32–34.
   PubMed Web of Science ®Google Scholar
• Castellano I, Gómez-Martino JR, Hernández MT, Novillo R, Covarsí A. [Remission of nephrotic syndrome caused by renal amyloidosis secondary to pulmonary tuberculosis after tuberculostatic treatment]. Nefrologia 2001;21:88–91.
   PubMedGoogle Scholar
• Kennedy AC, Burton JA, Allison ME. Tuberculosis as a continuing cause of renal amyloidosis. Br Med J 1974;3:795–797.
   PubMedGoogle Scholar
• Nik-Akhtar B, Khorsandi H, Nejatbakhsh A. Incidence of renal amyloidosis in pulmonary tuberculosis. J Trop Med Hyg 1977;80:147–148.
   PubMedGoogle Scholar
• Dixit R, Gupta R, Dave L, Prasad N, Sharma S. Clinical profile of patients having pulmonary tuberculosis and renal amyloidosis. Lung India 2009;26:41–45.
   PubMedGoogle Scholar
• Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, et al.; Eprodisate for AA Amyloidosis Trial Group. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007;356:2349–2360.
   PubMed Web of Science ®Google Scholar
• EMEA. Questions and answers on the withdrawal of the marketing application for Kiacta. 19 March 2008; Doc. Ref. EMEA/136938/2008.
   Google Scholar
• Sato H, Sakai T, Sugaya T, Otaki Y, Aoki K, Ishii K, Horizono H, et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 2009;28:1113–1116.
   PubMed Web of Science ®Google Scholar
• Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002;46:2571–2573.
   PubMed Web of Science ®Google Scholar
• Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006;54:2997–3000.
   PubMed Web of Science ®Google Scholar
• Mihara M, Shiina M, Nishimoto N, Yoshizaki K, Kishimoto T, Akamatsu K. Anti-interleukin 6 receptor antibody inhibits murine AA-amyloidosis. J Rheumatol 2004;31:1132–1138.
   PubMed Web of Science ®Google Scholar
• Nishida S, Hagihara K, Shima Y, Kawai M, Kuwahara Y, Arimitsu J, Hirano T, et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis 2009;68:1235–1236.
   PubMed Web of Science ®Google Scholar
• Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004;314:363–369.
   PubMed Web of Science ®Google Scholar
• Komaba H, Nakazawa T, Yamaguchi Y, Kumagai S, Fukagawa M. Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman’s disease: a report of three cases. NDT Plus 2008 6:423–426.
   Google Scholar
• Schrivers BF, Flwbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004;65:2003–2017.
   PubMedGoogle Scholar
• Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2011;50:552–562.
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 2003;29:185–202.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644–652.
   PubMed Web of Science ®Google Scholar